REVENUES OF TOP BIOPHARMACEUTICAL COMPANIES 2022
1 CHF = 1.01 USD, 1 GBP = 1.16USD; 1EUR= 0.99 USD; 1DKK = 0.13 USD; 1 JPY = 0.0075 USD
Merck revenues include only pharmaceuticals (excluding animal health)
Pfizer reported revenues of $25.7 billion in the first quarter of 2022, reflecting operational growth of 82%. The revenues from the vaccines segment were $14.94 billion, the hospital segment was $3.19 billion, the oncology segment was $2.97 billion, and immunology was $820 million.
The revenue drivers of the company were Comirnaty ($13.23 billion), Prevnar family ($1.57 billion), Paxlovid ($1.47 billion), Eliquis ($ 1.79 billion), and Ibrance ($1.24 billion).
Pfizer reported revenues of $27.7 billion in the second quarter of 2022. Paxlovid and Comirnaty primarily drove the revenues.
The total revenues in the first half of 2022 were $53.4 billion. The vaccine segment contributed $25.4 billion, the hospital products segment (including Paxlovid) contributed $12.9 billion,
In the first half of 2022, Comirnaty revenues were $22.07 billion, Paxlovid was $9.6 billion, Ibrance was 2.5 billion, and Eliquis was $3.5 billion. Eliquis revenues increased by 13%, but Ibrance revenues dropped by 4%, and Xeljanz revenues reduced by 29%.
Pfizer announced the revenues of the third quarter, reporting revenues of $22.6 billion, revenues declined by 2% versus last year.
In the first nine months, the revenues were $76 billion. The revenues from Comirnaty were $26.5 billion, Paxlovid was $17 billion, Eliquis was $5 billion, Prevanar family was $4.6 billion, Ibrance was $3.8 billion, and Xeljanz was $1.3 billion.
JOHNSON AND JOHNSON
Johnson and Johnson reported revenues of $23.4 billion in the first quarter of 2022, with sales growth of 5.0%. Pharmaceutical segment revenues were $12.87 billion, consumer health revenues were $3.59 billion, and Medtech revenues were $6.97 billion.
Stelara's revenues were $2.29 billion, and Darzalex's revenues were $1.86 billion.
Johnson and Johnson reported revenues of $24 billion in the second quarter of 2022. The sales increased by 3%. Revenues from the pharmaceutical segment were $13.3 billion, MedTech was $6.9 billion, and consumer health was $3.8 billion. Darzalex, Stelara, and Tremfya primarily drove the sales.
Johnson and Johnson reported revenues of $23.8 billion, with a growth of 1.9%. The pharmaceutical segment grew by 2.6%, with reported revenues of $13.21. MedTech was increased by 2.1%($6.8 billion), and consumer health revenues were reduced by 0.4% ($3.8 billion).
Roche sales increased by 11% at a constant exchange rate; pharmaceutical sales increased by 6%, and the diagnostics division grew by 24%. In the US, the pharmaceutical division sales increased by 2%, decreased by 1% in Europe, and increased by 69% in Japan primarily because of the high demand of COVID19 drug Ronapreve.
The main revenue drivers in the pharmaceutical segment were Ocrevus ($1.5 billion), Perjeta ($1.03 billion), Hemlibra ($0.89 billion), Tecentriq ($0.86 billion), and Actemra ($0.83 billion).
However, the company's full-year outlook mentioned sales growth in the low single digits, primarily because of a decrease in the demand for COVID19 drugs and diagnostics (sales decrease from CHF 2 billion 5 billion), plus losses due to biosimilars (CHF 2.5 billion).
Roche announced that the revenues were increased by 5% at CER in the first six months of 2022. The pharmaceutical division sales were increased by 3%, diagnostics sales increased by 11%. Ocrevus was the best selling drug with revenues of CHF 2.9 billion. Other best selling products were Perjeta (CHF 2 billion), Hemlibra (CHF 1.83 billion), and Tecentriq (CHF 1.8 billion).
9 MONTHS REVENUES
Roche reported nine months of revenues; the group sales increased by 2% at CER. The company reported revenues of $47.3 billion, the pharmaceutical segment contributed $33.3 billion (a contraction in sales by -1% in CHF), and diagnostics contributed $13.9 billion.
The company emphasized that the revenue reduction is because of a decrease in demand for COVID-19 diagnostics and medicines.
The company announced that the sales were driven by Ocrevus ($4.4 billion), Hemlibra ($2.8 billion), and Evrysdi ($0.8 billion). However, Avastin, Rituxan, and Herceptin biosimilars had a negative impact on revenues.
Merck reported revenues of $15.9 billion, and the pharmaceutical segment contributed $14.1 billion. Animal health contributed revenues of $1.5 billion.
The sales were primarily driven by Keytruda ($4.8 billion) and Lagevrio ($3.25 billion).
Merck reported revenues of $26.86 billion in the first six months of 2022. Keytruda's revenues were $10.06 billion (an increase of 26%) in the first six months of 2022. Gardasil revenues were $3.1 billion, and Lagevrio was $4.4 billion.
In the third quarter, the pharmaceutical segment of Merck reported revenues of $13 billion, an increase of 13% versus 2021. Keytruda reported revenues of $5.4 billion, Gardasil of $2.3 billion,
The revenues from the pharmaceutical segment in the first nine months were $39.8 billion. The revenues from Keytruda were $15.5 billion, Gardasil/Gardasil 9 was $5.4 billion, and Januvia was $2.2 billion.
The revenues of Keytruda were grown by 20%, and there was a strong momentum from metastatic indications, including certain types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, TNBC, and MSI-H cancers.
AbbVie's Q1 revenues in 2022 were $13.5 billion, an increase of 4.1%. The revenues from the immunology portfolio were $6.14 billion, neuroscience was $1.5 billion, and hematologic oncology was $1.65 billion.
Humira revenues were $3.99 billion, Imbruvica was $1.17 billion, and Skyrizi was $0.94 billion.
AbbVie reported an increase in revenues of 21.4% in the second quarter of 2022. The company reported revenues of $14.53 billion. Humira revenues were $10.09 billion, Skyrizi was $2.19 billion, and Imbruvica was $2.3 billion.
AbbVie reported third-quarter revenues of $14.8 billion, an increase of 3.3% versus last year. The major revenue drivers were Humira ($5.5 billion), Skyrizi ($1.4 billion), and Imbruvica ($1.1 billion).
For nine months, AbbVie reported revenues of $42.9 billion. Humira revenues from the first nine months were $15.7 billion, Skyrizi was $3.6 billion, and Imbruvica was $3.4 billion. Rinvoq recorded sales of$1.8 billion, and Venclexta's revenues were $1.5 billion.
Skyrizi's revenues increased by 76%, whereas Rinvoq's revenues increased by 55%.
Novartis sales increased by 5% at a constant exchange rate; innovative medicines sales grew by 4%.
The main revenue drivers are Cosentyx ($1.16 billion), Entresto ($1.09 billion), Gilenya ($0.6 billion), and Lucentis ($0.52 billion).
Novartis reported an increase of 5% in sales in the second quarter of 2022. The company reported revenues of $12.78 billion, and the total revenues in the H1 of 2022 were $25.3 billion.
In the H1 of 2022, revenues from Cosentyx were $2.4 billion, Entresto was $2.2 billion, and Gilenya was $1.16 billion. Kesimpta's revenues were grown by 280% ($ 434 million), Entresto's by 37%, and Kisqali's by 36% ($ 547 million).
Novartis presented the revenues of the third quarter, with revenues declining by 4% in terms of USD. The company reported revenues of $12.5 billion versus $13.03 billion last year.
For the nine months, the company reported a revenue drop of 1%; reported revenues of $37.9 billion versus $38.4 billion last year. The growth drivers of Novartis were Cosentyx ($3.7 billion) and Entresto ($3.4 billion).
Abbott reported revenues of $11.90 billion in Q1 of 2022. The sales from the nutrition segment were $1.89 billion, diagnostics were $5.29 billion, medical devices were $3.57 billion, and pharmaceuticals were $1.15 billion.
BMS reported the Q1 revenues of $11.6 billion in 2022. The company's revenues were driven by Eliquis ($3.2 billion), Revlimid ($2.8 billion), Opdivo ($1.9 billion), Pomalyst / Imnovid (0.83 billion), and Orencia (0.79 billion).
BMS reported second-quarter revenues of $11.9 billion, an increase in revenues by 2%.
The total revenues in the first half of 2022 were $23.5 billion, Eliquis revenues increased by 14% ($6.4 billion), Opdivo by 10% ($4.0 billion), and Yervoy by 8% ($1.04 billion). Revlimid revenues decreased by 14% ($5.3 billion).